Adjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma: a single-center retrospective study

Background Adjuvant chemotherapy improves survival after resection of pancreatic ductal adenocarcinoma (PDAC), but the comparative outcomes of gemcitabine monotherapy (G) and gemcitabine plus S-1 (GS) in routine practice remain uncertain. This study aimed to analyze the associations of chemotherapy regimen and treatment completion with survival. Methods We retrospectively evaluated patients undergoing curative-intent resection for PDAC at Peking University First Hospital between January 2010 and April 2022. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards models. Sensitivity analyses included modeling chemotherapy initiation as a time-dependent exposure and comparing restricted mean survival time (RMST) between the G and GS groups over a 36-month horizon. Results The cohort included 245 patients, of whom 173 received postoperative chemotherapy; 46 received G and 90 received GS. Date-derived survival analyses included 242 evaluable patients. Median OS was 30.00 months (95% CI, 19.88–36.07) and median DFS was 15.93 months (95% CI, 12.52–24.57). For GS versus G, adjusted HRs were 1.28 (95% CI, 0.72–2.28) for OS and 1.36 (95% CI, 0.78–2.37) for DFS. Conclusions No significant differences in OS or DFS were observed between G and GS in this cohort. The exploratory associations between chemotherapy completion and survival need confirmation in studies that account for treatment timing and potential confounding.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1969731
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma: a single-center retrospective study

Jianqiao Yang, Fusheng Zhang, Yiran Chen, Yinmo Yang et al.
2 links
Frontiers in Oncology
Pancreatic and Hepatic Oncology Research
article

Adjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma: a single-center retrospective study

Jianqiao Yang, Fusheng Zhang, Yiran Chen, Yinmo Yang, Weikang Liu, Xiaodong Tian, Xuewei Sun, Yongsu Ma
article en

Abstract

Background Adjuvant chemotherapy improves survival after resection of pancreatic ductal adenocarcinoma (PDAC), but the comparative outcomes of gemcitabine monotherapy (G) and gemcitabine plus S-1 (GS) in routine practice remain uncertain. This study aimed to analyze the associations of chemotherapy regimen and treatment completion with survival. Methods We retrospectively evaluated patients undergoing curative-intent resection for PDAC at Peking University First Hospital between January 2010 and April 2022. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards models. Sensitivity analyses included modeling chemotherapy initiation as a time-dependent exposure and comparing restricted mean survival time (RMST) between the G and GS groups over a 36-month horizon. Results The cohort included 245 patients, of whom 173 received postoperative chemotherapy; 46 received G and 90 received GS. Date-derived survival analyses included 242 evaluable patients. Median OS was 30.00 months (95% CI, 19.88–36.07) and median DFS was 15.93 months (95% CI, 12.52–24.57). For GS versus G, adjusted HRs were 1.28 (95% CI, 0.72–2.28) for OS and 1.36 (95% CI, 0.78–2.37) for DFS. Conclusions No significant differences in OS or DFS were observed between G and GS in this cohort. The exploratory associations between chemotherapy completion and survival need confirmation in studies that account for treatment timing and potential confounding.

Frontiers in OncologyVol. 16
Peking University First Hospital (CN)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon